Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 103,457	$ 79,221
Marketable securities	148,765	223,142
Prepaid expenses and other current assets	4,673	8,640
Other receivable	910	1,770
Total current assets	257,805	312,773
Restricted cash, non-current	69	73
Property and equipment, net	2,364	3,116
Operating lease right-of-use assets	2,644	3,978
Other non-current assets	20	20
Total assets	262,902	319,960
Current liabilities:
Accounts payable	6,229	1,453
Accrued expenses	15,882	19,826
Current portion of operating lease liabilities	1,893	1,851
Other current liabilities	1,623	485
Total current liabilities	25,627	23,615
Operating lease liabilities	950	2,488
Other liabilities	213	210
Total liabilities	26,790	26,313
Commitments and contingencies (Note 8)
Shareholders’ equity:
Ordinary shares, $0.000017100448 par value. 2,923,900,005 shares authorized as of September 30, 2023; 107,168,686 shares issued and outstanding as of September 30, 2023; 2,923,900,005 shares authorized as of December 31, 2022; 107,043,924 shares issued and outstanding as of December 31, 2022	2	2
Additional paid-in capital	745,786	732,476
Accumulated other comprehensive loss	(3,220)	(2,080)
Accumulated deficit	(540,230)	(470,525)
Total LianBio shareholders’ equity	202,338	259,873
Non-controlling interest	33,774	33,774
Total shareholders’ equity	236,112	293,647
Total liabilities and shareholders’ equity	$ 262,902	$ 319,960